ART Guidelines

ART Guidelines

Please review the disclaimer before proceeding with these guidelines



  • ×
    /r ritonavir-boosted
    3TC lamivudine
    ABC abacavir
    ADR adverse drug reaction
    AKI acute kidney injury
    ALT alanine transaminase
    ANC antenatal care
    ART antiretroviral therapy
    ARV antiretroviral
    AST aspartate transaminase
    ATV atazanavir
    ATV/r ritonavir-boosted atazanavir
    AZT zidovudine
    bd twice daily
    CD4+ cluster of differentiation 4
    CM cryptococcal meningitis
    CNS central nervous system
    CrAg cryptococcal antigen
    CrCl creatinine clearance rate
    CSF cerebrospinal fluid
    CTX cotrimoxazole
    d4T stavudine
    ddI didanosine
    DILI drug-induced liver injury
    DNA deoxyribonucleic acid
    DRV darunavir
    DRV/r ritonavir-boosted darunavir
    DTG dolutegravir
    eGFR estimated glomerular filtration rate
    ELISA enzyme-linked immunosorbent assay
    ETR etravirine
    FBC full blood count
    FTC emtricitabine
    GI gastrointestinal
    Hb haemoglobin
    HBsAg hepatitis B surface antigen
    HBV hepatitis B virus
    HIV human immunodeficiency virus
    ICU intensive care unit
    INH isoniazid
    INR international normalised ratio
    InSTI integrase strand transfer inhibitor
    IPT isoniazid preventive therapy
    IRIS immune reconstitution inflammatory syndrome
    LAM lipoarabinomannan
    LDL-C low-density lipoprotein cholesterol
    LFT liver function test
    LP lumbar puncture
    LPV lopinavir
    LPV/r ritonavir-boosted lopinavir
    MDRD modification of diet in renal disease
    MTCT mother-to-child transmission of HIV
    MVC maraviroc
    NGT nasogastric tube
    NNRTI non-nucleoside reverse transcriptase inhibitor
    NRTI nucleoside reverse transcriptase inhibitor
    NTDs neural-tube defects
    NtRTI nucleotide reverse transcriptase inhibitor
    NVP nevirapine
    OI opportunistic infection
    PAS p-aminosalicylic acid
    PCR polymerase chain reaction
    PI protease inhibitor
    PI/r ritonavir-boosted protease inhibitor
    PMTCT prevention of mother-to-child transmission of HIV
    PPIs proton pump inhibitors
    PrEP pre-exposure prophylaxis
    QTc corrected QT interval
    RAL raltegravir
    RCTs randomised controlled trials
    RIF rifampicin
    RFB rifabutin
    RNA ribonucleic acid
    RPV rilpivirine
    RTV or /r ritonavir
    sCr serum creatinine
    sCrAg serum cryptococcal antigen
    TAF tenofovir alafenamide
    TAM thymidine analogue mutation
    TB tuberculosis
    TB-IRIS tuberculosis immune reconstitution inflammatory syndrome
    TBM tuberculosis meningitis
    TC total cholesterol
    TDF tenofovir disoproxil fumarate
    TG triglycerides
    TST tuberculin skin test
    UDP uridine 5’-diphospho
    ULN upper limit of normal
    VL viral load
    WHO World Health Organization
    WOCP women of childbearing potential

    How to use these guidelines:

    You can use the online version or download the PDF. When using the online version on a mobile device, or smaller screen, click on the top left-hand ‘Menu’ button to navigate to each module and access the abbreviations list. Every image can be enlarged and all references appear as numbered citations in the text. Tables in the guidelines are best viewed in landscape orientation when accessed via mobile device or tablet. 

    Additional guidance: Please regularly check into this page to get the latest information on these guidelines, obtain hints regarding what is in the pipeline, and access links to interesting articles.

    Sign up for updates: Please be sure to sign up for updates to receive alerts regarding any updates relevant to these guidelines.

    Feedback: Feel free send us feedback here


    Authors: Jeremy Nel, Sipho Dlamini, Graeme Meintjes (Chairpersons), John Black, Rosie Burton, Natasha Davies, Eric Hefer, Gary Maartens, Pheto Mangena, Moeketsi Mathe, Michelle Moorhouse, Mahomed-Yunus Moosa, Muhangwi Mulaudzi, Jennifer Nash, Thandekile Nkonyane, Wolfgang Preiser, Mohammed Rassool, David Stead, Helen van der Plas, Cloete van Vuuren, Francois Venter, Joana Woods

    Affiliation: Southern African HIV Clinicians Society

    Corresponding author: Jeremy Nel

    Disclaimer: Specific recommendations provided here are intended only as a guide to clinical management, based on expert consensus and best current evidence. Treatment decisions for patients should be made by their responsible clinicians, with due consideration for individual circumstances. The most current version of this document should always be consulted.

    License: These guidelines are licensed under the Creative Commons CC BY-NC-ND 4.0 license. Licensee: Southern African HIV Clinicians Society.

    How to cite: Nel J, Dlamini S, Meintjes G, et al.; for the South African HIV Clinicians Society. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. Southern African Journal of HIV Medicine 2020;21(1), a1115.